The Pharmacy Times® Skin Cancer Resource Center is a comprehensive resource for clinical news and expert insights on cancers that occur on the skin, including basal cell carcinoma, squamous cell carcinoma, and melanoma.
September 19th 2024
Pembrolizumab is an anti-programmed death receptor 1 (PD-1) therapy designed to increase the immune system’s ability to detect and fight tumor cells.
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Cancer Diagnoses Significantly Decreased in First Few Months of COVID-19 Pandemic
September 14th 2023Investigators found an approximately 23% decrease in overall cancer incidence in April 2020, specifically for breast, colon, rectal, head and neck cancers, as well as melanoma and endocrine cancer diagnoses.
Read More
Patients With Cancer Using Nonmedical Stimulants Can Continue Using Opioids, Regardless of Prognosis
September 13th 2023Experts agreed that it was appropriate for patients who use methamphetamine or cocaine to continue opioid use if clinician monitoring was increased and tapering was avoided.
Read More
FDA Approves Hepzato Kit for Liver-Directed Treatment of Metastatic Uveal Melanoma
August 16th 2023Melphalan/hepatic delivery system (Hepzato Kit; Delcath Systems Inc) is currently the only liver-directed therapy approved by the FDA for the treatment of netastatic uveal melanoma and percutaneous hepatic perfusion.
Read More
Pediatric Medication Studies: A New Challenge for Institutional Review Boards, Ethics Committees
July 10th 2023Institutional review boards and ethics committees have seen it as their main task in the past few decades to protect children from questionable studies; however, they are faced with a new challenge with pediatric drug development.
Read More